Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
WALTHAM, Mass., May 01, 2018 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are:
- The Bank of America Merrill Lynch 2018 Healthcare Conference at the Encore Hotel in Las Vegas, Nevada on Tuesday, May 15, 2018. Tim Pearson, EVP and CFO of TESARO, will participate in an analyst-led moderated Q&A at 4:20 PM PT and in meetings with investors.
- The Leerink Boston Biopharma Bus Tour on Thursday, May 17, 2018. Lonnie Moulder, CEO, and Mary Lynne Hedley, Ph.D., President and COO of TESARO, will present at 1:00 PM ET and will answer questions from investors.
A live webcast of the presentation at the Bank of America conference will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. An archived replay of this webcast will be available on the Company’s website for 14 days following the conferences.
About TESARO
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
For additional information, please contact:
Jennifer Davis
Vice President, Corporate Communications and Investor Relations
+1.781.325.1116 or [email protected]
Kate Rausch
Associate Director, Investor Relations
1.781-257-2505 or [email protected]
